GENE ONLINE|News &
From Promise to Proof: The New Era of Value-Centric Biotech Investing in Asia
Panelists and industry leaders gather during the Investment Summit at BIO Asia-Taiwan 2026, where global biopharma investors evaluate cross-border capital allocation, valuation dynamics, and emerging investment strategies for biotechnology ventures.
The 2026 BIO Asia-Taiwan Investment Summit gathered top-tier investors to evaluate evolving capital allocation trends across the global life sciences sector. Following the post-pandemic capital deployment surge, biotechnology investment has stabilized into a disciplined, fundamentals-driven regime. Frank Lin, Chief Operating Officer of Audit Services at PwC Taiwan, emphasized this shift, stating that “healthcare development no … From Promise to Proof: The New Era of Value-Centric Biotech Investing in Asia Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.
GO Prime with only $1.49 now
LATEST
Wendy Short Bartie Repositions Bristol Myers Squibb Corporate Affairs to Integrate Patient Advocacy and Healthcare Access
2026-09-14
Wendy Short Bartie Restructures Bristol Myers Squibb Corporate Affairs to Link Reputation with Business Performance
2026-09-14
Wendy Short Bartie Integrates Patient Advocacy and Public Trust into Bristol Myers Squibb Business Strategy
2026-09-14
Mycenax Teams Up with Global Partners to Expedite R&D and Market Launch of Next-Generation ADCs
2026-09-14
Chinese Bispecific Antibody Tops Keytruda in First Head-to-Head OS Win; SMA Muscle-Strengthening Therapy Approved, B7-H3 ADC Shows Promise
2026-09-14
EVENT
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia
